This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and
contact information

Hepatic disease

Liver disease

Fibroblast growth factor 7 (FGF7)

Mouse studies suggest FGF7 could help activate liver progenitor cells (LPCs) to treat liver diseases. LPCs proliferate in response to liver injury and are believed to contribute to regeneration. In three mouse models of liver injury and in human patients with liver disease, LPCs expressed FGF7. In mice, inducing Fgf7 overexpression shortly after liver injury or after establishment of chronic liver disease increased LPC activation and decreased liver injury compared with no overexpression. Next steps could include testing FGF7 or its derivatives in mouse models of liver disease.
Swedish Orphan Biovitrum AB markets Kepivance palifermin, a truncated form of FGF7 that acts as a keratinocyte growth factor receptor (KGFR; FGFR2; CD332) agonist, to treat oral mucositis.

SciBX 6(5); doi:10.1038/scibx.2013.116
Published online Feb. 7, 2013

Patent and licensing status unavailable

Takase, H.M. et al. Genes Dev.; published online Jan. 15, 2013;
doi:10.1101/gad.204776.112
Contact: Tohru Itoh, The University of Tokyo, Tokyo, Japan
e-mail:
itohru@iam.u-tokyo.ac.jp